Weill Medical College of Cornell University

• Home
• Cancer and Blood Disorders
  • Solid Tumor
    • Bladder Cancer
    • Breast Cancer
    • Colon Cancer
    • Esophageal Cancer
    • Gastric/Stomach Cancer
    • Head and Neck Cancer
    • Kidney/Renal Cancer
    • Liver Cancer
    • Lung Cancer
    • Melanoma
    • Ovarian/Peritoneal/Fallopian Tube Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Sarcoma
    • Soft Tissue Cancer

  • Multiple Myeloma
  • Leukemia and Myeloproliferative Disorders
    • Acute Lymphocytic Leukemia
    • Acute Myeloid Leukemia
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Chronic Myeloid Leukemia
    • Myelodysplastic Syndrome
    • Myelofibrosis
    • Polycythemia Vera

  • Lymphoma
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Hodgkin’s Lymphoma
    • Non-Hodgkin’s Lymphoma
    • Waldenstrom’s Macroglobulinemia

  • Bone Marrow Transplant (BMT)
  • Benign Hematology
    • Anticoagulation
    • Bleeding and Platelet Disorders
• Cardiovascular/Heart
  • Aortic Aneurysms
  • Arrhythmias
  • Atrial Fibrillations
  • Coronary Artery Disease (CAD)
  • Inherited Heart Disease
  • Myocardial Infarction
  • Other Cardiovascular Diseases and Conditions
• Diabetes
• Gastrointestinal Diseases
  • Hepatitis
    • Hepatitis B
    • Hepatitis C
    • Hepatitis/HIV Co-Infection
  • Cancers of the Colon, Pancreas, Esophagus, Stomach
  • Celiac Disease
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Ulcerative Colitis
  • Other Gastrointestinal Diseases
• Geriatrics
  • Pain and Palliative Care
• Hepatitis
  • Hepatitis B
  • Hepatitis C
  • Hepatitis/HIV Co-infection
• Hypertension/High Blood Pressure
• HIV/AIDS and Infectious Diseases
• Kidney/Renal Disease
  • Kidney Transplants
• Lifestyle/Behavior Change
  • Medication Adherence
  • Hypertension Control
  • Colon Cancer Screening/Risk Reduction
• Pulmonary (Lung/Respiratory Tract) Disease
  • Asthma
  • Pneumonia
  • Pulmonary Fibrosis
  • Smokers
  • Other Respiratory/Lung Conditions
• Rheumatology Autoimmune Disease and Orthopedic Surgery
 
• Sleep Disorders
• Weight Loss/Obesity
• Healthy Volunteers

Phase I/II Study of Veltuzumab Combined with 90Y-Epratuzumab Tetraxetan in Patients with Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma

Study Status

Open to Enrollment

Study Description

This is a clinical trial for people with non-Hodgkin lymphoma (NHL) whose NHL has not responded adequately to standard treatments.

People with relapsed aggressive lymphoma can in some cases experience long term remission with aggressive chemotherapy treatments. However, there is no standard treatment for patients who either are not eligible for this aggressive treatment due to other health problems, or who have not responded well to chemotherapy, and better therapy options are needed.

The purpose of this study is to test the safety of ⁹⁰Y-epratuzumab at different dose levels combined with veltuzumab. The study will also provide early evidence of how effective the combination of ⁹⁰Y-epratuzumab and veltuzumab is in treating people with aggressive lymphomas who have not responded well to earlier treatment.

The treatment portion of this study consists of study drug administrations each week for 4 consecutive weeks. Participants will then return for study visits at intervals up to 12 weeks for blood samples and evaluation for 2 years, and then every 6 months for up to 5 years or until disease progression.

Sponsor

Immunomedics

Key Eligibility

• Men and women age 18 and older
• CD20+ B-cell non-Hodgkin lymphoma (NHL), with diffuse large B-cell lymphoma (DLBCL) or other aggressive lymphomas
• Progressed after or did not respond optimally to at least 1 prior standard treatment regimen for NHL
• If DLBCL, ineligible for or refused high-dose chemotherapy with stem cell transplant
• Detailed eligibility reviewed when you contact the study team

Principal Investigator

Peter Martin, MD

Contact

• June Greenberg, RN
• (212) 746-2651
• [email protected]